N-Acetyl Semax
An acetylated (and often amidated) analog of the Russian nootropic Semax, engineered to resist enzymatic breakdown for longer-lasting cognitive and neuroprotective effects.
N-Acetyl Semax is a structurally modified derivative of Semax (the synthetic ACTH(4-7)/Pro-Gly-Pro heptapeptide, MEHFPGP), carrying an N-terminal acetyl group and, in the popular amidate version, a C-terminal amide (Ac-MEHFPGP-NH2). These modifications are proposed to slow aminopeptidase and carboxypeptidase cleavage, extending half-life and allowing less-frequent dosing than plain Semax. It is a distinct research compound rather than an alias of Semax, though its pharmacology and evidence are largely extrapolated from the parent peptide, which upregulates BDNF/NGF and modulates dopaminergic and serotonergic signaling. No independent human clinical trials exist for the modified form specifically.
Class
Synthetic modified heptapeptide (acetylated/amidated Semax analog)
Half-life
~20-30 minutes (NA-Semax, intranasal, estimated); ~30-45 minutes for the amidate form
Routes
Intranasal, Subcutaneous (research-only)
Category
Cognitive & Nootropic
Researched benefits
What it's studied for
Cognitive enhancement
Marketed and community-used for improvements in focus, mental clarity, and cognitive performance. Effects are extrapolated from Semax pharmacology; direct evidence for the modified form is preclinical and anecdotal.
BDNF and NGF upregulation
Like the parent Semax, it is reported to increase brain-derived neurotrophic factor and nerve growth factor expression in cortex and hippocampus, the neuroplasticity pathway implicated in learning, memory, and mood.
Dopaminergic drive
Reported to increase dopamine release in mesolimbic motivation circuits (VTA to nucleus accumbens) with possible D2 receptor sensitization at chronic doses, consistent with the subjective 'drive boost' users describe.
Serotonergic and noradrenergic modulation
Small but reproducible increases in serotonin (5-HT) and norepinephrine turnover have been observed in rodent cortical tissue, contributing to reported mood and alertness effects.
Neuroprotection
Preclinical ischemic models show neuroprotective effects similar to Semax, of longer duration for the modified analog. Semax itself has been studied in Russian trials for ischemic stroke and cognitive disorders.
Anti-inflammatory activity
Reported suppression of pro-inflammatory cytokines (IL-6, TNF-alpha) in models of acute neuroinflammation.
Longer duration than Semax
The N-acetyl (and C-terminal amide, in the amidate version) modifications are proposed to resist peptidase degradation, supporting a 1-2x daily schedule where standard Semax often needs 3-4 doses per day.
Mechanism
How it works
N-Acetyl Semax retains the ACTH(4-7) core sequence of Semax (Met-Glu-His-Phe-Pro-Gly-Pro) but adds an N-terminal acetyl group; the popular amidate variant additionally replaces the C-terminal carboxylic acid with an amide (Ac-MEHFPGP-NH2). The acetyl group blocks aminopeptidase cleavage at the N-terminus and the amide blocks carboxypeptidase cleavage at the C-terminus, together conferring greater metabolic stability and a longer functional half-life than the unmodified peptide.
Once absorbed, the compound is proposed to act through the same pathways as Semax. Chief among these is upregulation of BDNF and NGF in the cortex and hippocampus, driving the neuroplasticity mechanisms associated with cognitive enhancement, neuroprotection, and antidepressant effects. It also modulates monoaminergic neurotransmission, enhancing dopaminergic signaling in mesolimbic motivation circuits and producing modest increases in serotonin and norepinephrine turnover.
Additional reported mechanisms include modulation of NMDA receptor activity and anti-inflammatory effects via suppression of IL-6 and TNF-alpha in neuroinflammation models. The intranasal route is proposed to permit partial direct CNS delivery via the olfactory epithelium, and the acetyl modification is claimed to improve blood-brain-barrier transport.
Importantly, no publications indexed in PubMed specifically characterize N-Acetyl Semax as a distinct molecule with independent human pharmacokinetic or clinical data. All mechanistic claims are extrapolations from Semax research or from limited preclinical rodent work on the modified analogs; direct head-to-head pharmacokinetic comparisons in peer-reviewed literature remain absent.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Supplied as a lyophilized powder or pre-made nasal spray. Vials are typically reconstituted with bacteriostatic water; the resulting solution is dosed by measured nasal spray actuations or, for the subcutaneous research route, by insulin syringe. Store lyophilized powder refrigerated and reconstituted solution cold, away from light.
Beginner
- Dose
- 200-400 mcg/day
- Frequency
- Once daily
- Timing
- Morning (AM)
- Duration
- 14 days
- Route
- Intranasal
Entry-level exposure to gauge individual response; keep dosing early in the day to avoid interfering with sleep.
Intermediate
- Dose
- 400-800 mcg/day
- Frequency
- Once or twice daily
- Timing
- Morning, optional midday
- Duration
- 21-30 days on / 7-14 days off
- Route
- Intranasal
Cycled use with a washout period; the amidate form's longer half-life supports fewer daily doses than standard Semax.
Advanced
- Dose
- 800-1,200 mcg/day
- Frequency
- 1-2x daily
- Timing
- Morning and/or midday
- Duration
- 30-day cycles
- Route
- Intranasal or subcutaneous (research-only)
Higher-end research dosing; sometimes stacked with Selank or P-21 Amidate. Avoid late-day dosing due to stimulating effects.
- These figures reflect the amidate (Ac-MEHFPGP-NH2) form, which is the most commonly protocol-documented variant; plain NA-Semax has a shorter half-life and may need more frequent dosing.
- Cycle the compound (e.g., days on with a scheduled washout) rather than using it continuously.
- Dose earlier in the day because of stimulating, dopaminergic effects that can disrupt sleep.
- Dosing is not standardized by any regulator; all numbers derive from vendor monographs and community research protocols, not clinical trials.
Combinations
Stacking & blends
Semax + Selank Nootropic-Anxiolytic Stack
Balance stimulating cognitive drive with anxiolytic calm
Selank, the tuftsin-derived anxiolytic analog, is commonly paired with the Semax family to offset the stimulating, dopaminergic edge of N-Acetyl Semax while complementing its focus and mood effects.
Semax + P-21 Cognitive Stack
Broaden neurotrophic and cognitive support
P-21 (a cyclic Pro-Gly derivative of the same Semax/Selank motif) is used alongside the advanced N-Acetyl Semax protocol to layer additional BDNF-related neuroplasticity support.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Pregnancy or nursing
- Active mania
- Cardiovascular conditions
- Known peptide allergy
Reported side effects in available preclinical data and community research use are mild and generally similar to Semax. Long-term safety in humans at sustained research-use dosing is not characterized at Western clinical trial standards. Discontinue use with any adverse reaction and consult a qualified professional.
FAQ
N-Acetyl Semax — common questions
Is N-Acetyl Semax the same as Semax?
No. It is a structurally modified analog of Semax carrying an N-terminal acetyl group (and, in the amidate version, a C-terminal amide). It is a distinct molecule with related effects and a longer half-life, not an alias or interchangeable product.
How is it different from N-Acetyl Semax Amidate?
The amidate form adds a C-terminal amide (-NH2) on top of the N-acetyl modification, further resisting enzymatic cleavage. This extends functional duration further (estimated ~30-45 min half-life vs ~20-30 min for NA-Semax), which is why the amidate is often dosed just 1-2 times per day.
Why choose N-Acetyl Semax over plain Semax?
The main practical difference is half-life. The structural modifications slow degradation, so the compound requires less-frequent dosing for sustained effects, where standard Semax often needs 3-4 doses per day.
What is it used for?
It is researched and used in community settings for cognitive enhancement, focus, mood, and neuroprotection, based largely on the pharmacology of the parent compound Semax (BDNF/NGF upregulation and dopaminergic/serotonergic modulation).
Is it approved or legal?
It is not approved by the FDA or any major Western regulator for human use. It is generally legal to purchase as a research chemical for laboratory use in most jurisdictions but is not approved for human consumption.
How is it typically taken?
Most commonly as an intranasal nasal spray, mirroring the intranasal route of approved Semax in Russia. A subcutaneous route is sometimes used in research contexts.
Is there strong clinical evidence for it?
No. There are no human clinical trials indexed in PubMed for the modified compound specifically. Evidence is preclinical (rodent cognition, BDNF and neuroprotection) plus extrapolation from Semax; formal Western Phase 2/3 trials have not been conducted.
How can I verify vendor product is genuine?
Because the acetyl/amide modifications add only ~70 Da versus native Semax, basic HPLC may not distinguish them. Look for independent third-party testing with mass spectrometry identity confirmation to verify you are not receiving cheaper native Semax.
